Lab study found CoronaVac serum neutralization efficiency was significantly decreased against B.1.526, P.1, and B1.351 SARS-CoV-2 variants. 28 May, 2021 | 08:26h | UTC Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac – The Lancet Infectious Diseases